GREENFERN INDUSTRIES LIMITED

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2021

GREENFERN INDUSTRIES LIMITED INTERIM CONSOLIDATED REPORT CONTENTS FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2021

	Page
Directors' Profiles	2-3
Financial Statements	
Interim Consolidated Statement of Comprehensive Income	5
Interim Consolidated Statement of Changes in Equity	6
Interim Consolidated Statement of Financial Position	7
Interim Consolidated Statement of Cash Flows	8
Notes to the Interim Consolidated Financial Statements	9 - 22
Corporate Information	23

GREENFERN INDUSTRIES LIMITED DIRECTORS' PROFILES

Brent King

Brent was the founder and managing director of Dorchester Pacific Limited and its subsidiary Dorchester Finance Limited, until he resigned in 2005. During his tenure he built that company from zero to over \$480 million in assets and returns of 20% per annum for over 10 years. Dorchester Pacific Limited was a public issuer with a registered prospectus for more than 15 years. During that time Dorchester Pacific Limited and other companies Brent was a director of registered in excess of 100 prospectuses/disclosure and documents companies it sponsored also issued prospectuses. Brent has also been a director of 42 Below Limited, Finzsoft Solutions Limited, Chow Group Limited, Charlie's Group Limited, the Board of the Eden Park Trust, Auckland Cricket and New Zealand Cricket. Brent is currently a director of General Capital Limited, Corporate Holdings Limited, General Finance Limited, Investment Research Group Limited (IRG), Equity Investment Advisers Limited and King Capital & Investment Corporation Limited. IRG is an NZX sponsor. Brent has also held directorships with a number of private companies.

Brent joined the board of listed company Snakk Media Limited in August 2018 in an attempt to assist in the turn-around of the business. He resigned on 7 February 2019. The business entered voluntary administration and subsequently became a listed shell seeking a new investment.

Daniel Casey

Dan has a background as a project manager and civil engineer within the civil construction sector and has over 15 years industry experience, both in New Zealand and abroad. Dan is experienced in all facets of the project lifecycle of large-scale developments and capital works and has previously directly managed multiple and concurrent project portfolios up to the value of \$30 million.

His passion and ability to lead large and diverse teams has seen him become a successful leader within a number of privately and publicly owned companies. He intends to leverage his networks and their expertise in the procurement, scheduling and delivery of all facility builds for Greenfern as well as driving the overall delivery of the long-term business strategies. As Managing Director, Dan is ultimately responsible for the overall management of the business to ensure that it delivers on shareholder and client expectations.

Darryl Davies

In 2018 Darryl co-founded Cannvalate Pty Limited, Australia's first medicinal cannabis company supported and funded primarily by medical professionals. Darryl is currently the Chief Operating Officer and Managing Director of Cannvalate. Cannvalate currently provides a substantial share of the medicinal cannabis products prescribed in Australia. Darryl is also a director of Valens Australia Pty Limited, a subsidiary of the Toronto Stock Exchange listed The Valens Company Inc., a global leader in the development and manufacturing of cannabinoid-based products. Prior to co-founding Cannyalate. Darryl was Programme Director at The Medicinal Cannabis Leadership Programme, Australia's first comprehensive cannabis education programme, and before that Director of Communications at BuddingTech, a medicinal cannabis accelerator. Darryl has also held senior roles at Stretch-A-Family, an organisation delivering therapeutic programmes to children and young people in foster care placements. Darryl has also been a Board Member of Inaugural Australia Therapeutic Life Story Work, an organisation assisting children to overcome the trauma of abuse. and Proiect Outreach Coordinator at ADDACTION, the largest substance misuse charity in the United Kingdom.

Kirsten Taylor

Kirsten Taylor is an experienced company owner, CEO, specialist consultant, author, Member of not-for-profit Board organisations. She is a qualified Medical Herbalist, Naturopath, Nutritionist and specialist in Natural Fertility Homeobotanical medicine. Seven years of clinical practice experience led Kirsten to develop an award-winning range of sciencebased sleep and stress formulations, with the company she created, SleepDrops International, becoming the top selling sleep category brand in New Zealand pharmacies and health stores and winner of multiple awards, including Best Emerging Business at the Westpac Business Awards in 2014. In 2015, Kirsten was appointed to the board of the Auckland **Business** Chamber of Commerce and she became a trustee for the Auckland Children's Santa Parade Trust in 2017. Kirsten's extensive experience of governance, business, marketing product innovation enables her to bring a wealth of expertise to this role.

Simon McArley

Simon graduated from Victoria University, Wellington in 1984 with an LLB (Hons). Simon is a lawyer by training who specialises in corporate governance and risk. After almost 20 years in private practice with Kensington Swan, specialising in banking and securities law, Simon took up regulatory positions with NZX as acting Head of Regulation and the (then) Securities Commission as acting Director Primary Markets. Simon went on to join the Serious Fraud Office (SFO) as General Manager Capital Markets and Corporate Fraud in 2011 where he had responsibility for the successful investigation and prosecution of finance sector fraud uncovered by the GFC. After 12 months as acting Director of the CFO, Simon left the SFO in 2013 and has since been consulting with government and private sector entities on governance and risk management issues. Simon has also held governance positions with commercial and not for profit entities. Simon is a member of the New Zealand Law Society. Simon is also a keen sailor and has extensive coastal and blue water experience.

Marvin Yee

Marvin Yee is the principal of Crown Financial Services (CFS) which undertakes Funds Management and Private Equity. Outside New Zealand, CFS has operations in the United States, Singapore and Australia. Marvin's area of expertise is in transactional banking and private equity. His investment experience includes technology, fintech, medtech and the crafting of financial instruments.

He is also a partner of Crown Private, a global investment syndicate with investments in over 95 countries and investor members from over 18 countries.

Marvin sits on a number of company boards both in New Zealand, Australia, the United States, Malaysia and Singapore. A graduate from Auckland and Massey University, he has an MBA specialising in accounting and finance and a BA in politics. He is a Past Chairman of the New Zealand Young Professionals and a Past President of the Rotary Club of Birkenhead.

Philip Brown

Philip founded Tenderlink, a tender notification services company, which he sold in 2010 for \$21.6 million. After the sale, Philip built the Novotel New Plymouth Hobson Hotel. Philip was also a founding investor in the Chiefs rugby franchise. Philip has a wealth of experience as a businessman and a property developer. He is passionate about Taranaki and his family and friends live there.

GREENFERN INDUSTRIES LIMITED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE SIX MONTH ENDED 30 SEPTEMBER 2021

		Unaudited 6 Months September 2021	Unaudited 6 Months September 2020
	Notes	NZ\$	NZ\$
Operating Revenue	2	44,475	5,254
Cost of Sales Gross profit	3	(31,077) 13,398	(13,016) (7,762)
Gross pront		13,390	(1,102)
Other Income	2	5,307	37,432
_			
Expenses Selling and Distribution Expenses	3	(25,084)	(94,780)
Administration Expenses	3	(809,160)	(271,299)
		(834,244)	(366,079)
Operating loss		(815,539)	(336,408)
Finance Expense		(159)	-
·		(159)	-
Loss before income tax		(815,698)	(336,408)
Loss for the year		(815,698)	(336,408)
Total comprehensive loss for the year	_	(815,698)	(336,408)
Loss and total comprehensive loss attributable to: Equity holders of the parent		(815,698)	(336,408)
Equity holders of the parent		(815,698)	(336,408)
		· · /	, , ,
Loss per share: Basic and Diluted Earning per share in NZ\$	5	(0.08703152)	(0.04620650)

The interim financial statements are to be read in conjunction with the notes to the financial statements set out on pages 9 to 22.

GREENFERN INDUSTRIES LIMITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 September 2021

	Notes	Unaudited At 30 September 2021 NZ\$	Audited At 31 March 2021 NZ\$
SHAREHOLDERS EQUITY			
Issued share capital	6	7,784,973	5,363,473
Accumulated losses		(3,827,634)	(3,011,937)
Total Equity attributable to shareholders of the company		3,957,339	2,351,536
Non-controlling Interest Total shareholders funds		3,957,339	2,351,536
Represented by:			
CURRENT ACCETS			
CURRENT ASSETS Cash and cash equivalents	7	2,268,609	1,297,054
Trade, other and related party receivables	9	4,143	168,656
Inventories	8	66,889	48,430
Prepayments and other current assets	O	447,215	131,349
Total current assets		2,786,856	1,645,489
NON-CURRENT ASSETS			
Prepayments and other non-current assets		10,417	72,917
Financial assets	16	64,200	89,227
Property, plant and equipment	10	1,747,954	1,605,535
Intangible assets	11	5,683	2,877
Total non-current assets		1,828,254	1,770,556
Total assets		4,615,110	3,416,045
CURRENT LIABILITIES	40	250 444	121 000
Trade, other and related party payables Received in advance	12 13	259,411 398,361	131,009
	13		121 000
Total current liabilities		657,771	131,009
NON-CURRENT LIABILITIES Other liabilities			933,500
Total non-current liabilities			933,500
rotal non-current habilities			933,500
Total liabilities		657,771	1,064,509
Net assets		3,957,339	2,351,536
For and behalf of the Board, dated		MM	·

The interim financial statements are to be read in conjunction with the notes to the financial statements set out on pages 9 to 22.

Director

Director

GREENFERN INDUSTRIES LIMITED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2021

	Issued Share Capital	Accumulated Loss	Equity Holders	Non- Controlling Interests	Total
	\$	\$	\$	\$	\$
Balance as at 1 April 2020	2,328,139	(1,756,156)	571,983	-	571,983
Comprehensive income				•	
Net (loss)/profit for the financial period		(336,408)	(336,408)		(336,408)
Total comprehensive income	-	(336,408)	(336,408)	-	(336,408)
Transactions with owners					
Ordinary Shares Issued	367,803	-	367,803	-	367,803
Total transactions with owners	367,803	-	367,803	-	367,803
Balance as at 30 September 2020 (unaudited)	2,695,942	(2,092,564)	603,378		603,378
Balance as at 1 April 2020	2,328,139	(1,756,156)	571,983	-	571,983
Comprehensive income					
Net loss for the financial year		(1,255,781)	(1,255,781)		(1,255,781)
Total comprehensive income	-	(1,255,781)	(1,255,781)	-	(1,255,781)
Transactions with owners Contributions of equity net of transaction costs	3,035,334		3,035,334		3,035,334
			· · · · · · · · · · · · · · · · · · ·		
Total transactions with owners	3,035,334	-	3,035,334	-	3,035,334
Balance as at 31 March 2021(audited)	5,363,473	(3,011,937)	2,351,536	-	2,351,536
Comprehensive income					
Net loss for the financial period	-	(815,698)	(815,698)		(815,698)
Total comprehensive income/(loss)	-	(815,698)	(815,698)	-	(815,698)
Transactions with owners					
Contributions of equity net of transaction costs	2,421,500		2,421,500		2,421,500
Total transactions with owners	2,421,500	-	2,421,500	-	2,421,500
Balance as at 30 September 2021 (unaudited)	7,784,973	(3,827,634)	3,957,339	-	3,957,339

The interim financial statements are to be read in conjunction with the notes to the financial statements set out on pages 9 to 22.

GREENFERN INDUSTRIES LIMITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2021

	Notes	Unaudited 6 Months September 2021 NZ\$	Unaudited 6 Months September 2020 NZ\$
		+	
Cash flows from operating activities			
Cash was received from:		207.240	400.000
Receipts from customers		307,349	129,236
Other receipts		5,307	37,432
Cash was applied to:			
Payments to suppliers and employees		(697,946)	(266,201)
Payments to related parties		(174,608)	(127,399)
Interest paid		(159)	-
Net cash outflow from operating activities		(560,058)	(226,932)
Cash flows from investing activities			
Cash was applied to:			
Purchase of property, plant and equipment		(198,322)	(315,358)
Purchase of intangible assets		(3,000)	-
Purchase of financial assets		(50,000)	(14,200)
Net cash inflow/(outflow) from investing activities		(251,322)	(329,558)
Cook flows from financing activities			
Cash flows from financing activities Cash was received from:			
Proceeds from share issue		1,788,000	367,803
Net cash inflow from financing activities		1,788,000	367,803
Net decrease in cash and cash equivalents		976,620	(188,686)
Foreign currency translation adjustment		(5,065)	-
Cash and cash equivalents at the beginning of the year		1,297,054	991,937
Cash and cash equivalents at the end of the year		2,268,609	803,251
•			

The interim financial statements are to be read in conjunction with the notes to the financial statements set out on pages 9 to 22.

1. ACCOUNTING POLICIES

REPORTING ENTITY

Greenfern Industries Limited (the "Company") is a company incorporated and domiciled in New Zealand and registered under the Companies Act 1993. The Company is listed and its ordinary shares are quoted on the NZX main board equity security market (NZX main market) and the addresses of its registered office and principal place of business are disclosed in the Corporate Information section of this report. The Company is an FMC Reporting Entity under the Financial Markets Conduct Act 2013 and its financial statements comply with the Companies Act 1993 and the Financial Markets Conduct Act 2013.

The interim consolidated financial statements of Greenfern Industries Limited for the six month ended 30 September 2021 comprise the Company and its subsidiaries (together referred to as the "Group"). For the purposes of complying with generally accepted accounting practice in New Zealand ("NZ GAAP"), the Group is a for-profit entity. As a listed company, the Group is considered a Tier One entity. The principal activity of the Group is a producer and wholesaler of therapeutic products.

1.1 Statement of compliance

These consolidated interim financial statements have been prepared in accordance with NZ GAAP. These consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting. They do not include all disclosures that would otherwise be required in a complete set of financial statements and should be read in conjunction with Greenfern Industries Limited 's Annual Report for the year ended 31 March 2021.

The condensed interim consolidated financial statements were approved and authorised for issue by the directors on _25/11/2021 ___. The directors are not able to amend the financial statements after issue.

1.2 Basis of preparation

The interim consolidated financial statements are prepared on a cost basis except for financial assets which are carried at amortised cost. The interim consolidated financial statements for the Group are presented in New Zealand dollars (\$), which is the functional currency of all entities within the Group. All financial information has been rounded to the nearest dollar unless otherwise stated.

1.3 Significant accounting policies

The preparation of the interim financial statements in compliance with IAS 34 requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in note 1.4.

1.4 Critical accounting judgments and key sources of estimation uncertainty

The same significant judgments, estimates and assumptions included in the notes to the financial statements in the Group's financial statements for the year ended 31 March 2021 have been applied to these Interim Consolidated Financial Statements.

1. ACCOUNTING POLICIES (continued)

1.5 Going concern

The consolidated financial statements have been prepared on a going concern basis. The Group is considered to be in its start-up phase and as such the Group has reported a loss for the six month period ended 30 September 2021 of \$815,698(the same period of 2020: loss of \$336,408) and operating cash outflows for this period was \$560,0058 (the same period of 2020: \$226,932).

The consolidated unaudited financial statements have been prepared on a going concern basis. The Directors has reasonable expectation that the Group had adequate resources to continue in operational existence for the foreseeable future.

At 30 September 2021, the Group had no external debt. It had a positive working capital of \$2.1 million. Cash and cash equivalents at that date was more than \$2.3 million. The Group's sales has also increased in the six month period. And there were \$2.4 million equity has been raised through wholesale placements of shares for the six months ended 30 September 2021.

In assessing the adoption of the going concern principle in the preparation of the financial statements, the Directors have reviewed cash flow forecasts for the 20 months from the date of signing the financial statements. The Group needs to raise additional equity funding to implement its long term business strategies. The cash flow forecasts have assumed that \$1.25 million equity will be raised through further capital raising activity by 31 March 2022.

Directors have considered the impact of not being able to raise the capital in the above timeframes and have determined that the Group will still be able to continue to operate with current cash reserves for the 12 months from the date of signing the financial statements by:

- · deferring planned capital expenditure; and
- · reducing operating costs.

Given the nature of the judgments and estimates noted above and management's ability to take mitigating actions, it is the considered view of the Directors that the Group has adequate resources to meet its ongoing obligations for at least a period of 12 months from the date of signing these financial statements.

On this basis, the Directors have assessed it is appropriate to adopt the going concern basis in preparing its financial statements.

2. REVENUE

	Note	September 2021 NZ\$	September 2020 NZ\$
Operating revenue			
Sales of Goods		9,227	5,254
Sales of Electricity		35,248	-
Total operating revenue	_	44,475	5,254
Other Income		5,307	-
Covid-19 wage subsidy		-	37,432
Total other income	_	5,307	37,432
Total Income	_	49,782	42,686

2. REVENUE (continued)

Performance Obligations and Revenue Recognition

Revenue is measured based on the consideration specified in a contract with a customer. The Group recognises revenue when it transfers control over a good or service to a customer.

Operating revenue - Geographical locations

Operating revenue is attributed to the following geographical locations on the basis of the country the customer is trading in.

	Sales of Goods	Sales of Electricity	Total
	NZ\$	NZ\$	NZ\$
30 September 2021			
New Zealand	9,227	35,248	44,475
Operating Revenue	9,227	35,248	44,475
30 September 2020			
New Zealand	5,254	-	5,254
Operating Revenue	5,254	-	5,254

3. EXPENSES

	Note	September 2021 NZ\$	September 2020 NZ\$
Profit / (Loss) before income tax has			
Included in Cost of Sales Expenses			
Direct purchase cost of goods sold		27,725	13,016
Overhead allocated		3,352	-
Total Cost of Sales	_	31,077	13,016
Included in Selling and Distribution Expenses			
Advertising		13,936	93,056
Other expenses		11,148	1,723
Total Selling and Distribution Expenses	_	25,084	94,780
Included in Administration Expenses			
Accounting and Consulting		108,119	30,003
Amortisation of Intangible Assets	11	194	_
Depreciation for property, plant and equipment	10	55,903	12,843
Direct Listing Fee		169,715	-
Project Management Fees		88,696	92,060
Insurance		108,240	700
Salaries		161,867	61,654
Other expenses		116,427	74,039
Total Administration Expenses	_	809,160	271,299
		Interim R	enort September 202

3. EXPENSES (continued)

Finance costs: Interest paid on borrowings from related parties	159	
interest paid on bonowings norm related parties	100	
	159	-

4. INCOME TAX EXPENSE

The Group recognised no income tax expense during this period due to operating loss. The Group has an income tax rate of 28% which is the tax rate that would be applicable to the expected total annual earnings (September 2019: 28%).

The Group has a tax losses of \$3,011,937 bought forward from 31 March 2021. Losses can be carried forward indefinitely under New Zealand tax law (assuming shareholder continuity requirements are met and approval of the Inland Revenue Department is obtained).

The Group has not recognised a deferred tax asset on its Statement of Financial Position as at reporting date. In deciding whether to recognise the deferred tax assets, the Group has determined if the utilisation of deferred assets is probable and whether it is likely that sufficient and suitable taxable profits will be available in the future against which the reversal of temporary differences can be deducted.

5. EARNINGS PER SHARE

The earnings and weighted average number of ordinary shares used in the calculation of basic earnings per share are as follows:

	September 2021 NZ\$	September 2020 NZ\$
Basic earnings per share Profit/ (Loss) after taxation attributable to equity holders of the parent Weighted average number of ordinary shares on issue	(815,698) 9,372,448	(336,408) 7,280,541
Basic and Diluted Earning per share in NZ\$	(0.08703152)	(0.04620650)

The Company is listed and its ordinary shares are quoted on the NZX main board equity security market (NZX main market) at 21 October 2021. There have been other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of authorisation of these financial statements.

6. AUTHORISED AND ISSUED SHARE CAPITAL

Balance as at 31 March 2021	Shares Issued No.	\$
Ordinary shares		
Balance at 1 April 2020 Ordinary shares on issue	7,205,983	2,328,139
Treasury shares		
Ordinary shares on issue at 1 April 2020 excluding treasury shares	7,205,983	2,328,139
Movement for 2021 financial year		
Ordinary shares authorised and issued	1,665,615	3,035,334
Ordinary shares on issue at 31 March 2021	8,871,598	5,363,473

6. AUTHORISED AND ISSUED SHARE CAPITAL (continued)

Movement to 30 September 2021	Shares Issued No.	\$_
Ordinary shares authorised and issued	1,001,700	2,421,500
Ordinary shares on issue at 30 September 2021 excluding treasury shares	9,873,298	7,784,973

All ordinary shares issued are fully paid. All ordinary shares rank equally with one vote attached to each fully paid ordinary share and have equal dividend rights and no par value. The Group has not declared or proposed to pay any dividends for the period ended 30 September 2021 (September 2020: Nil).

At reporting date, the company held no treasury shares.

7. CASH AND CASH EQUIVALENTS

	September 2021 \$	March 2021 \$
Cash at bank and on hand Bartercard Dollars	2,071,998 196,611	1,297,054
Total cash and cash equivalents	2,268,609	1,297,054

Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less held at call with financial institutions, and Bartercard Dollars.

8. INVENTORIES

	September 2021 \$	March 2021 \$
Work in progress Finished goods Total Inventories	42,031 24,858 66,889	42,031 6,399 48,430

Inventories are measured at the lower of cost and net realisable value. Cost comprises all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.

No inventories has been assessed to have a net realisable value lower than its cost during this period. The provision for closing stock has a zero-balance.

Assessing write downs for inventory obsolescence and net realisable value involves making estimates and judgements in relation to future selling prices between the most recent store stock counts and reporting date.

9. TRADE, OTHER AND RELATED PARTY RECEIVABLES

	Note	September 2021 \$	March 2021 \$
Trade receivables - third parties		4,143	12,163
GST receivable		-	154,493
Other receivable		-	2,000
		4,143	168,655
Allowance for impairment losses		-	-
Total trade and related party receivables	_	4,143	168,655

Trade debtors are non-interest bearing and receipt is normally on 30 days terms. Related party receivables are non-interest bearing and repayable on demand as disclosed in note 14.

The Group applies the simplified approach under NZ IFRS 9 to measuring the allowance for credit losses for receivables from contracts with customers, contract assets and lease receivables. Under the NZ IFRS 9 simplified approach, the Group determines the allowance for credit losses for receivables from contracts with customers, contract assets and lease receivables on the basis of the lifetime expected credit losses of the instrument. Lifetime expected credit losses represent the expected credit losses that are expected to result from default events over the expected life of the financial asset.

The directors consider that there is no material difference between the carrying value and fair value of trade debtors and related party receivables. The Group's management considers that all financial assets that are not impaired or past due for each of the reporting dates under review are of good credit quality. The directors also consider that the receivables that are past due and not impaired are fully recoverable. No allowance for impairment has been recognised.

10. PROPERTY, PLANT AND EQUIPMENT

	Office Equipment \$	Facility Otago \$	Power Station \$	Facility Taranaki \$	Assets under improvement	Total \$
As at 31 March 2021						
Cost						
Cost as at 1 April 2020	28,351	_	5,192	282,761	-	316,304
Additions	7,309	48,378	804,828	475,701	-	1,336,216
Disposal	-	-	-	-	-	-
Written off		-	-		-	<u> </u>
Cost as at 31 March 2021	35,659	48,378	810,021	758,462	-	1,652,520
Accumulated Depreciation						
Accumulated Depreciation at 1 April 2020	(6,809)	-	-	-	-	(6,809)
Depreciation charge for the year	(12,766)	(874)	_	(26,536)	_	(40,176)
Disposal	-	-	_	-	_	-
Written off	_	_	_	_	_	_
Accumulated Depreciation at 31 March 2021	(19,575)	(874)	-	(26,536)	-	(46,985)
Carrying Amount						
Cost	35,659	48,378	810,021	758,462	-	1,652,520
Accumulated Depreciation	(19,575)	(874)	-	(26,536)	-	(46,985)
Carrying Amount 31 March 2021	16,085	47,504	810,021	731,926	-	1,605,536
As at 30 September 2021						
Cost						
Cost as at 1 April 2021	35,659	48,378	810,021	758,462	-	1,652,520
Additions	3,464	2,217	50,716	123,617	18,307	198,321
Written off	-	-	-	-	-	-
Cost as at 30 September 2021	39,123	50,596	860,737	882,079	18,307	1,850,841
Accumulated Depreciation						
Accumulated Depreciation at 1 April 2020	(19,575)	(874)	-	(26,536)	-	(46,985)
Depreciation charge for the period	(9,436)	(1,687)	(11,983)	(32,797)	-	(55,903)
Written off	-	-	-	-	_	-
Accumulated Depreciation at 30 September 2021	(29,011)	(2,561)	(11,983)	(59,333)	-	(102,888)
Carrying Amount						
Cost	39,123	50,596	860,737	882,079	18,307	1,850,841
Accumulated Depreciation	(29,011)	(2,561)	(11,983)	(59,333)		(102,888)
Carrying Amount 30 September 2021	10,112	48,035	848,754	822,746	18,307	1,747,954

During the financial year ended 31 March 2021, the Group exercised its option to purchase the land it was renting in addition to the Power Station and additional land surrounding the Power Station for a purchase price of \$750,000. The Power Station was put into use and started depreciation from 1 April 2021.

There was no written off or disposal of asset during the six month period ended 30 September 2021.

11. INTANGIBLE ASSETS

	Graphic		
	design	Trademarks	Total
Year ended 31 March 2021	\$	\$	\$
			_
Cost			
Cost as at 1 April 2020	-	2,650	2,650
Additions	662	-	662
Cost as at 31 March 2021	662	2,650	3,312
Accumulated Amortisation			
Accumulated amortisation 1 April 2020	-	(135)	(135)
Amortisation for the year	(35)	(265)	(300)
Accumulated amortisation as at 31 March 2021	(35)	(400)	(435)
Carrying Amount			
Cost	662	2,650	3,312
Accumulated amortisation	(35)	(400)	(435)
Carrying Amount 31 March 2021	627	2,250	2,877
Period ended 30 September 2021			
Cost			
Cost as at 1 April 2021	662	2,650	2,650
Additions	3,000	-	-
Cost as at 30 September 2021	3,662	2,650	2,650
Accumulated Amortisation			
Accumulated amortisation 1 April 2021	(35)	(400)	(435)
Amortisation for the period	(81)	(113)	(194)
Accumulated amortisation as at 30 September 2021	(116)	(512)	(628)
Carrying Amount			
Cost Cost	3,662	2,650	6,312
Accumulated amortisation	(116)	(512)	(628)
Carrying Amount 30 September 2021	3,546	2,138	5,683
our ying Amount so deptember 2021	3,340	2,130	3,003

The amortisation charge of \$194 is recognised under administration expenses in the Statement of Comprehensive Income.

12. TRADE, OTHER AND RELATED PARTY PAYABLES

	Note	September 2021 \$	March 2021 \$
Trade payables		191,292	51,619
Accruals		· -	72,106
Related party payables		53,288	- -
Other payables		14,831	7,284
Total trade, other and related party payables		259,411	131,009

The normal trade credit terms granted to the Group range from 30 to 90 days. The trade creditors are unsecured and non-interest bearing. The carrying amount disclosed above is a reasonable approximation of fair value.

13. RECEIVED IN ADVANCE

		September	March
		2021	2021
	Note	\$	\$
Received in advance		398,361	-
Total received in advance		398,361	-

Among the balance, \$300,000 payment recevied in advanced received is share subscription paid by GB Family Trust. It will be recognised as share capital on the listing date.

14. RELATED PARTIES

Related party transactions have arisen where a person(s) has control or significant influence over the reporting entity or where two entities are controlled or jointly controlled by a person(s) that has control or significant influence over the reporting entity.

Related Parties:

Brendon Partridge	Founding shareholder
Brent King	Shareholder and director of IRG and the Group
Cannabis and Bioscience	Shareholder and common directorship
CBC Greenfern	Shareholder and common directorship
Dan Casey	Founding shareholder & managing director
Daniel Leyden	Founding shareholder and director
Investment Research Group (IRG)	Shareholder and common directorship
John Hussey	Founding shareholder
Philip Brown	Shareholder and director
Renewable Power Limited	Shareholder and common directorship
Sarah Leyden	Spouse of Daniel Leyden
Timothy Johnson	Founding shareholder and director
GFI Pharma Limited	Subsidiary with 100% ownership
Greenfern Hemp Limited	Subsidiary with 100% ownership
Greenfern Power Limited	Subsidiary with 100% ownership
Mato Limited	Subsidiary with 100% ownership
Greenfern IndustriesThailand	Associate with 49% ownership

Related party balances

The following balances were held with related parties at period end.

Data de Data de Data de La composição de	N. C. T. C.	September 2021	March 2021
Related Party Receivables	Nature of Transactions	\$	\$
Investment Research Group (IRG)	Management Fees	2,588	-
Investment Research Group (IRG)	Capital raising fee	50,700	
		53,288	-

The related parties payables are unsecured and repayable on demand. There is no collateral or guarantees for related parties payables. Related parties payables for purchases of goods, directors fees and management fees are non-interest bearing.

14. RELATED PARTIES (continued)

Related party transactions

Related party transactions	Nature of Transactions	September 2021 \$	September 2020 \$
Cannabis and Bioscience	Share capital received	401,400	-
Cannabis and Bioscience	Shares purchased	-	10,000
CBC Greenfern	Share capital received	-	75,000
Investment Research Group	Lodgment, Capital raising,	139,200	17,500
Investment Research Group	Share capital received	100,000	-
John Hussey(Fluidity)	Project management fee	88,696	92,602
Renewable Power Limted	lease payments for Hydro Power	-	17,297
Total related party transaction	is	327,896	212,399

Key Management Personnel

Key management personnel are defined as those persons having authority and responsibility for planning, directing and controlling the activities of the Group, directly or indirectly, and include the directors and the Chief Executive. Remuneration paid to key management personnel is as follows:

	September 2021 \$	September 2020 \$
Salaries and other short-term benefits	90,825	19,305
Total	90,825	19,305

15. COMMITMENTS AND CONTINGENCIES

The Group has no capital commitments at 30 September 2021 (31 March 2021: Nil)

16. FINANCIAL INSTRUMENTS

Categories of financial assets and liabilities

The carrying amounts presented in the statement of financial position relate to the following categories of assets and liabilities:

	Financial assets at amortised cost NZ\$	Financial liabilities at amortised cost NZ\$	Total NZ\$
30 September 2021 <u>Financial Assets:</u> <u>Amortised cost</u>	NZ-Φ	NΔφ	ΝΖΦ
Cash and cash equivalents Trade and related party receivables Shares in unlisted entities	2,071,998 4,143 200	- - -	2,071,998 4,143
Fair value through profit or loss Shares in unlisted entities Cash and cash equivalents(Bartercard) Total financial assets	64,000 196,611 2,336,952	- - -	64,000 196,611 2,336,752

16. FINANCIAL INSTRUMENTS (continued)

Financial liabilities: Amortised cost Trade and other payables Total financial liabilities 31 March 2021	<u>-</u>	259,411 259,411	259,411 259,411
Financial Assets: Amortised cost Cash and cash equivalents Trade and related party receivables Shares in unlisted entities	1,372,081 14,163 200	- - -	1,372,081 14,163 200
Fair value through profit or loss Shares in unlisted entities	14,000	-	14,000
Total financial assets	1,400,444	-	1,400,444
Financial liabilities: Amortised cost Trade and other payables		123,724	123,724
Total financial liabilities		123,724	123,724

The fair value of the financial instruments of the Group approximates their carrying value. The use of financial instruments exposes the Group to credit, interest rate and liquidity risks. The Group's overall risk management programme seeks to minimise potential adverse effects on the Group's financial performance.

17. INVESTMENT IN SUBSIDIARIES

Name of subsidiary	Principal activity	Ownership interest and voting	
		September March	
GFI Pharma Limited	Non-Trading	2021 100%	2021 100%
Greenfern Hemp Limited	Non-Trading	100%	100%
Greenfern Power Limited	· ·	100%	100%
Mato Limited	Non-Trading	100%	100%
	Non-Trading Non-Trading		

All subsidiaries were incorporated in March 2021 and are non trading.

18. SEGMENT REPORTING

The Group's operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker is the person or group that allocates resources to and assesses the performance of the operating segments on an entity. The Group has determined the Group's Board of Directors as its chief operating decision-maker as the board is responsible for allocating resources and assessing the performance of the operating segments and making strategic and operating decisions. Income and expenses directly associated with each segment are included in determining each segment's performance.

18. SEGMENT REPORTING (continued)

The Group operates in a number of business segments in New Zealand and Australia. The Group has determined its operating segments into two segments which reflect the different type of industry sectors within which the Group operates. The Company is considered to be in the corporate segment. Information regarding the operations of each reportable operating segment is included below.

Cannabis and therapeutics products

The operations of this segment reflect the activities of manufacture and distribution of hemp products.

Electricity generation

This segment includes the generation and distribution of electricity.

Corporate Segment

The corportate segment include providing accounting, management and administration services to other segments of the Group.

No operating segments have been aggregated to form the above reportable operating segments. The Group's Financing has been allocated to segments. Sales between the segments of the Group are made on in a similar manner to transactions with third parties.

The following tables present revenue and profit information for the Group's operating segments for the six months ended 30 September 2021 and 2020, respectively:

\$	\$	\$	\$
products	generation	segment	September 2021
therapeutics	Electricity	Corporate	Period ended 30
and			
Cannabis			

For the six months ended 30 September 2021

Segment profit/(loss) before tax	(252,151)	(32,460)	(530,928)	(815,539)
Total operating expenses	230,301	67,709	536,235	834,244
Other expenses	144,992	46,086	425,202	616,280
Depreciation	34,484	11,983	9,436	55,903
Amortisation and impairment			194	194
Salary expenses	50,825	9,640	101,402	161,867
Operating Expenses				-
Cost of sales	31,077	-	-	31,077
Total Revenue	9,227	35,248	5,307	49,782
Other Income			5,307	5,307
Operating Income Revenue from external customers	9,227	35,248	-	44,475

18. SEGMENT REPORTING (continued)

	Cannabis and therapeutics products	Electricity generation	Corporate segment	Period ended 30 September 2021
	\$	\$	\$	\$
For the six months ended 30 September 202	<u>0</u>			
Operating Income				
Revenue from external customers	5,254	-	-	5,254
Other Income	-	-	37,432	37,432
Total Revenue	5,254	-	37,432	42,686
Cost of sales	13,016	-	-	13,016
Operating Expenses				
Salary expenses	52,489	-	9,165	61,654
Depreciation	6,477	354	6,012	12,843
Other expenses	127,367	1,357	162,858	291,582
Total operating expenses	186,333	1,711	178,035	366,079
Segment profit/(loss) before tax	(194,094)	(1,711)	(140,603)	(336,408)

The following tables present assets and liabilities information for the Group's operating segments as at 30 September 2021 and 31 March 2021, respectively:

	Cannabis and			
	therapeutics products	Electricity generation	Corporate segment	Total
	\$	\$	\$	\$
As at 30 September 2021				_
Segment assets	1,282,279	848,754	2,484,077	4,615,110
Capital Expenditure	-	-	-	-
Segment Liabilities	244,579	-	413,192	657,771
As at 31 March 2021				
Segment assets	965,022	810,021	1,641,002	3,416,045
Capital Expenditure	-	-	-	-
Segment Liabilities	123,724	-	940,784	1,064,509

19. NET TANGIBLE ASSETS PER SHARE

The net tangible assets and number of shares are as follows:	September 2021 \$	March 2021 \$
Total assets	4,615,110	3,416,045
Less right-of-use assets	- -	, , , -
Less intangible assets	5,683	2,877
Tangible assets	4,609,427	3,413,168
Less total liabilities	657,771	1,064,509
Add lease liabilities	-	-
Net tangible assets	3,951,655	2,348,659
Number of ordinary shares on issue	9,873,298	8,871,598
Net tangible assets / liabilities per share in NZ\$	0.40023662	0.26470000

20. CONTINGENT LIABILITIES

The Group has no contingent liabilities at 30 September 2021 (31 March 2021: Nil)

21. EVENTS AFTER THE REPORTING PERIOD

There has been no matter or circumstance, which has arisen since 30 September 2021 that has significantly affected or may significantly affect:

(a)the operations, in financial years subsequent to 30 September 2021, of the Group, or

(b)the results of those operations, or

(c)the state of affairs, in financial years subsequent to 30 September 2021, of the Group.

22. SEASONALITY OF INTERIM OPERATIONS

There are no significant seasonality or cyclicality of business affecting the interim operations.

GREENFERN INDUSTRIES LIMITED CORPORATE INFORMATION

SOLICITORS

McRae Law Limited PO Box 106-586 Level 9, 38 Wyndham Street, Auckland

SHARE REGISTRAR

Computershare Investor Services Limited Level 2, 159 Hurstmere Road Private Bag 92-119 Auckland 1142

FINANCIAL ADVISER

Investment Research Group Limited PO Box 106 488 Level 8, General Capital House 115 Queen Street Auckland 1040

AUDITORS

Crowe
Private Bag 90106
173 Spey Street, Invercargill

BANK

BNZ Bank Hamilton Store Garden Place 354 Victoria Street Hamilton Phone 0800 275 269

Greenfern Industries Limited

Security code: GFI
Listed on NZX Market
NZ Company number: 6804155

HEAD OFFICE / REGISTERED OFFICE

Greenfern Industries Limited Level 8, General Capital House 115 Queen Street Auckland 1040

TELEPHONE

+64 (9) 3040145

WEBSITE

www.gfi.nz